1-Benzyl-5-chloro-1,2,3,4-tetrahydro-1,6-naphthyridine | 1201785-17-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 1-Benzyl-5-chloro-1,2,3,4-tetrahydro-1,6-naphthyridine
• 英文别名: 1-benzyl-5-chloro-3,4-dihydro-2H-1,6-naphthyridine
• CAS: 1201785-17-2
• 化学式: C₁₅H₁₅ClN₂
• 分子量: 258.74
• InChiKey: QZMXMKGMWYHVBR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  16.1
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• HETEROCYCLIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS
  申请人：Pfizer Inc.

  公开号：EP3137469A1

  公开（公告）日：2017-03-08
• US9745317B2
  申请人：——

  公开号：US9745317B2

  公开（公告）日：2017-08-29
• [EN] HETEROCYCLIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES ET LEUR UTILISATION COMME LIGANDS DES RÉCEPTEURS D1 DE LA DOPAMINE
  申请人：PFIZER

  公开号：WO2015166366A1

  公开（公告）日：2015-11-05

  The present invention provides, in part, compounds of Formula (I): and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1 -associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), schizotypal personality disorder, cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), ADHD, Parkinson's disease, anxiety, and depression.